Health

Iovance Biotherapeutics

$47.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-0.21%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell IOVA and other stocks, options, and ETFs commission-free!

About IOVA

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. The listed name for IOVA is Iovance Biotherapeutics, Inc. Common Stock.

CEO
Maria Fardis
Employees
148
Headquarters
San Carlos, California
Founded
2007
Market Cap
7.16B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.29M
High Today
$48.86
Low Today
$47.03
Open Price
$47.94
Volume
1.08M
52 Week High
$54.21
52 Week Low
$18.70

Collections

IOVA Earnings

-$0.55
-$0.37
-$0.18
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 23, After Hours

You May Also Like

NFJ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure